
Commentary|Podcasts|June 27, 2024
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.
Advertisement
This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
2
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
3
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
4
Glargine Insulin Linked to Fewer Severe Lows in Youth With T1D
5


































































































